JAZZ

In the past six months, Jazz Pharmaceuticals' stock has seen significant movement. The stock had risen by 10.14% in the past month and 78.24% over the last year. Key events impacting the stock include strong Q1 2026 financial results with total revenues reaching $1.07 billion, FDA acceptance and priority review for Ziihera, full year and fourth quarter 2025 financial results with total revenues growing 5% in 2025, and constructive analyst sentiment.